TD Asset Management
CRNX icon

TD Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

TD Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.15M Sell
191,142
-43,750
-19% -$1.63M 0.01% 730
2026
Q1 		$8.53M Buy
234,892
+44,414
+23% +$1.98M 0.01% 688
2025
Q4 		$8.87M Sell
190,478
-13,070
-6% -$582K 0.01% 691
2025
Q3 		$8.48M Buy
203,548
+1,066
+0.5% +$34.1K 0.01% 692
2025
Q2 		$5.82M Buy
202,482
+27,788
+16% +$858K 0.01% 749
2025
Q1 		$5.86M Sell
174,694
-54,310
-24% -$2.03M 0.01% 761
2024
Q4 		$11.7M Buy
229,004
+18,882
+9% +$1.06M 0.01% 624
2024
Q3 		$10.7M Buy
210,122
+5,124
+2% +$264K 0.01% 630
2024
Q2 		$9.18M Sell
204,998
-30,200
-13% -$1.39M 0.01% 633
2024
Q1 		$11M Buy
235,198
+58,772
+33% +$2.3M 0.01% 609
2023
Q4 		$6.28M Buy
176,426
+37,000
+27% +$1.13M 0.01% 706
2023
Q3 		$4.15M Buy
139,426
+80,526
+137% +$1.66M 0.01% 774
2023
Q2 		$1.06M Buy
58,900
+31,300
+113% +$624K ﹤0.01% 1119
2023
Q1 		$443K Buy
+27,600
New +$511K ﹤0.01% 1283
2019
Q3 		– Sell
-8,419
Closed -$210K – 1340
2019
Q2 		$210K Buy
+8,419
New +$208K ﹤0.01% 1294
2019
Q1 		– Sell
-9,619
Closed -$288K – 1346
2018
Q4 		$288K Sell
9,619
-1,300
-12% -$36.6K ﹤0.01% 1309
2018
Q3 		$313K Buy
+10,919
New +$324K ﹤0.01% 1363

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Asset Management's CRNX Position: Q2 2026 in Review

TD Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 19% in Q2 2026, selling an estimated $1.63M and leaving 191,142 shares worth $7.15M. The position accounts for 0.01% of the portfolio, ranked #730.

TD Asset Management first reported a position in CRNX in Q3 2018 and has held it in 17 quarters since. The position peaked at $11.7M in Q4 2024. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • TD Asset Management held 191,142 shares of Crinetics Pharmaceuticals worth $7.15M as of Q2 2026.
  • TD Asset Management sold 43,750 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.63M.
  • Crinetics Pharmaceuticals made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #730 holding.
  • TD Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • TD Asset Management's Crinetics Pharmaceuticals position peaked at $11.7M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.